Liquid Biopsy for Prostate and Bladder Cancer: Progress and Pitfalls

Area of Science:

• Oncology
• Biomarkers
• Cancer Diagnostics

Background:

• Urinary liquid biopsy (LB) has improved bladder and prostate cancer detection and reduced overtreatment.
• Next-generation blood-based LB tests focus on circulating tumor cells, DNA, and RNA for risk stratification.
• Clinical implementation of blood-derived biomarkers faces barriers including cost, standardization, and reimbursement.

Purpose of the Study:

• To review the successes and challenges of urinary and blood-based liquid biopsy tests for bladder and prostate cancer.
• To highlight the potential of liquid biopsy in managing metastatic disease by detecting resistance and recurrence markers.

Main Methods:

• Literature review of urinary and blood-based liquid biopsy tests for bladder and prostate cancer.
• Analysis of current successes and pitfalls in clinical implementation.
• Examination of biomarkers like circulating tumor cells, DNA, and RNA.

Main Results:

• Urinary LB tests have demonstrated efficacy in reducing overtreatment and improving cancer detection.
• Blood-based LB tests are emerging for risk stratification in metastatic disease.
• Significant barriers hinder the widespread clinical adoption of blood-derived biomarker tests.

Conclusions:

• Liquid biopsy tests, both urinary and blood-based, are minimally invasive and effective for detecting significant cancer.
• Addressing implementation challenges is crucial for realizing the full potential of liquid biopsy in oncology.
• Further research and standardization are needed for blood-based liquid biopsy tests.